

GeoVax has 2-3 Vaccine Candidates in development to respond to the COVID-19 Pandemic. Here is some of the media coverage.

Print:

[In the race to treat COVID-19, Georgia companies stake a claim](#)



[GeoVax Progresses in Coronavirus \(COVID-19\) Vaccine Development Program](#)



[Asia Deal Watch: China's BravoVax, US-based GeoVax Team Up On Coronavirus Vaccine - Paywall](#)



[The race to stop COVID-19 - GeoVax listed here](#)

THE RACE TO STOP COVID-19

As a new strain of coronavirus threatens public health systems across the globe, researchers are racing to develop a vaccine.

DAWN CONNELLY & JULIA ROBINSON

In context


Compared with some outbreaks of novel respiratory disease, the death rate for coronavirus disease 2019 (COVID-19) is currently low. This could reduce further as the global outbreak progresses and milder cases are detected. Pandemic (H1N1) 2009 influenza was estimated to infect 1.1 billion people, with a death rate of 1 in 5000 (0.02%). Seasonal flu has a similar death rate, but infects up to 4 billion.




Symptoms and transmission

- Common symptoms: fever (90%), weakness (89.0%), cough (59.4%), muscle pain (54.8%), difficulty breathing (52.8%).
- Less common symptoms: headaches (10.5%), diarrhea (9.4%), stomach pain (2.2%), dizziness (10.3%), nausea and vomiting (10.1%).
- Incubation period: 0-14 days.
- Severity: data from 44,000 cases of COVID-19 in China suggest that 82.9% of cases are mild, 13.8% are severe and 4.7% are critical. Severe cases are more prevalent in older people and those with an existing long-term condition, such as cardiovascular disease, diabetes, respiratory disease or hypertension.
- Transmission: person-to-person spread between close contacts (1.8 metres) through respiratory droplets.
- Diagnostic: COVID-19 is suspected based on clinical symptoms and relevant travel history or close contact with infected individuals. Cases are only confirmed when there is a positive laboratory test.
- Treatment: treatment of COVID-19 is symptomatic, such as providing oxygen. Medicines specifically licensed for COVID-19 are not currently available, but clinical trials of several antiviral drugs are being conducted in China.

Case fatality rates for COVID-19




Global takeover



Vaccine development

There are five main approaches being taken to develop a vaccine against SARS-CoV-2, with several biotechnology companies, academic organisations and pharmaceutical companies employing different technologies in the race to bring their vaccine candidate to clinical trials. The World Health Organization (WHO) hopes that a vaccine will be available by October 2021.



1. Viral vector vaccine:

- **Organisations working on vaccine:** Johnson & Johnson, University of Oxford and Biavax, University of Oxford and Advent SA, Tonia Pharmaceuticals and Southern Research, Alimetrics, Greiner, Vaxart, CanSino Biologics, Zydus Cadila, Inotivite Pasteur
- **Estimated date of first human trials:** June 2020

2. DNA vaccine:

- **Organisations working on vaccine:** Inovio Pharmaceuticals with Beijing Advanced Biotechnology, Applied DNA Sciences, Takis Biotech and Eriwayx, Zydus Cadila
- **Estimated date of first human trials:** April 2020

3. RNA vaccine:

- **Organisations working on vaccine:** CureVac, Moderna and US National Institute of Allergy and Infectious Diseases; Moderna Therapeutics, Tongji University and Chinese Center for Disease Control and Prevention, Imperial College London
- **Estimated date of first human trials:** April 2020

4. Live-attenuated vaccine:

- **Organisations working on vaccine:** Codagen with Serum Institute of India
- **Estimated date of first human trials:** By August 2020

5. Protein-based vaccine:

- **Organisations working on vaccine:** Novavax; Clover Biopharmaceuticals with GSK; Baylor College of Medicine, University of Texas Medical Branch, New York Blood Center and Fudan University, China; University of Saskatchewan, Canada; University of Queensland, Australia, and Dynavax; Vaxart; Genzyme; ExproSion; Vaxil Bio; Sanofi Pasteur; BioCr-Pharming
- **Estimated date of first human trials:** By June 2020

Immune response:

- It is not known how strong the immune response needs to be to protect against SARS-CoV-2; therefore, some of the vaccines being developed may not work.
- Before candidates reach clinical trials, investigators must also ensure they induce protective immunity, not immunopathology, as was seen in early attempts to develop a SARS-CoV vaccine after it emerged in 2002.

Landscape of COVID-19 candidate vaccines




TV Interviews

[Beaufort man working on coronavirus vaccine through his Atlanta-based company](#)

March 9, 2020 WSAV Atlanta, GA. by: [Alex Bozarjian](#)

Beaufort man working on coronavirus vaccine through his Atlanta-based company



[Biotech CEO on race to develop coronavirus vaccine](#)

March 11, 2020 David Dodd, CEO of GeoVax, joins **Shannon Bream** on 'Fox News @ Night' to discuss the expected timeline for the creation of a vaccine against coronavirus.




[Biotech company GeoVax working on coronavirus vaccine](#)

March 4, 2020 Fox News - Neil Cavuto GeoVax CEO David Dodd weighs in on efforts to combat coronavirus.




[Metro Atlanta company joins race to develop coronavirus vaccine](#)

January 30, 2020 Atlanta, GA. 11Alive.com WXIA



[A Metro Atlanta Biotech Company Is Working On A Coronavirus Vaccine](#)

February 18, 2020 Atlanta NPR



['Where's the money?' Inside GeoVax, one lab working to create a COVID-19 vaccine](#)

March 9, 2020 Fox 25/ABC 16 WGXA



[Chinese partnership on coronavirus vaccine working well: GeoVax CEO](#)

March 3, 2020 Fox Business, Mornings with Maria

FOX BUSINESS
Mornings with Maria

BATTLING THE CORONAVIRUS
TRUMP: VERY GOOD WORK HAS BEEN DONE ON THE VACCINE

LIVE CORONAVIRUS OUTBREAK

DOW FUTURES
26,619.00
▲ 151.00
+0.57%

DAX 12,073.63 ▲ 215.76 +1.76% | NIKKEI 21,082.73 ▼ 261.35 -1.26%

METALS ► GOLD (GC/1) 1,605.20 ▲ 10.40 | SILVER (SI/100) 17.85 ▲ 0.05

[US company working on coronavirus vaccine hopes to accelerate timeline](#)

March 8, 2020 Fox News, Fox Facts

FOX FACTS

NIH WARNS THAT TIMELINES FOR DEVELOPING CORONAVIRUS TREATMENTS ARE "FUNDAMENTALLY DIFFERENT" THAN VACCINES

LIVE CORONAVIRUS OUTBREAK

FOX NEWS SUNDAY
DR. ANTHONY FAUCI
TODAY 2 & 7PM ET

[For coronavirus, vaccine funding is most important: Expert](#)

March 5, 2020 Fox Business News, Liz Macdonald



[Cobb County lab is working on creating vaccine for coronavirus](#)

March 3, 2020 WSBTV2 Atlanta



